GSK promises to cap price of its drugs in poorest countries

BMJ 2009; 338 doi: (Published 18 February 2009) Cite this as: BMJ 2009;338:b686
  1. Andrew Jack
  1. 1Financial Times

    GlaxoSmithKline, the United Kingdom based pharmaceutical group, has unveiled a series of policies to boost access to its drugs in poorer and richer countries alike (

    In a speech at Harvard Medical School last week, Andrew Witty laid out his approach for the first time since taking over as the company’s chief executive last spring, saying: “Society expects us to do more . . . To be frank, I agree. We have the capacity to do more and we can do more.”

    Last May Mr Witty replaced Jean-Pierre Garnier, who had already earned plaudits for strengthening GSK’s commitment to making drugs affordable (BMJ 2008;336:1396 doi:10.1136/bmj.a397), after criticism at the start of the decade …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription